GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDL BioPharma Inc (NAS:PDLI) » Definitions » PS Ratio

PDL BioPharma (PDL BioPharma) PS Ratio : 5.69 (As of May. 05, 2024)


View and export this data going back to 1992. Start your Free Trial

What is PDL BioPharma PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, PDL BioPharma's share price is $2.47. PDL BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 was $0.43. Hence, PDL BioPharma's PS Ratio for today is 5.69.

The historical rank and industry rank for PDL BioPharma's PS Ratio or its related term are showing as below:

PDLI's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.03
* Ranked among companies with meaningful PS Ratio only.

PDL BioPharma's Revenue per Sharefor the three months ended in Jun. 2020 was $0.05. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 was $0.43.

Back to Basics: PS Ratio


PDL BioPharma PS Ratio Historical Data

The historical data trend for PDL BioPharma's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDL BioPharma PS Ratio Chart

PDL BioPharma Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 1.25 1.09 1.66 5.47

PDL BioPharma Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.68 2.01 5.47 4.79 6.21

Competitive Comparison of PDL BioPharma's PS Ratio

For the Biotechnology subindustry, PDL BioPharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDL BioPharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDL BioPharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where PDL BioPharma's PS Ratio falls into.



PDL BioPharma PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

PDL BioPharma's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=2.47/0.434
=5.69

PDL BioPharma's Share Price of today is $2.47.
PDL BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.43.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


PDL BioPharma  (NAS:PDLI) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


PDL BioPharma PS Ratio Related Terms

Thank you for viewing the detailed overview of PDL BioPharma's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PDL BioPharma (PDL BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
932 Southwood Boulevard, Incline Villiage, NV, USA, 89451
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Executives
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
John Peter Mclaughlin director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Dominique Monnet officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Christopher Lewis Stone officer: VP, Gen. Counsel & Secretary 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Alan Lee Bazaar director 9 BEDFORD ROAD, KATONAH NY 10536
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Edward Imbrogno officer: VP Finance, CAO and Acting CFO 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Jill M. Jene officer: VP, Business Development 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Harold E Selick director
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304
Paul W Sandman director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Peter S Garcia officer: Vice President, CFO ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jody S Lindell director 2536 FILLMORE ST., SAN FRANCISCO CA 94115
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010